(Click the link to comment and to vote – voting not working through email, sorry!)
COVID is on the rise again, with a more transmissible and immune-evading variant. Nirmatrelvir-ritonavir (brand name Paxlovid) is approved for children 12 years and older AND weighing 40 kg or more in high-risk situations.
January 31, 2023 at 1:40 pm
D) Unvaccinated patient with BMI > 95th percentile for age
The highest risk conditions for progression to severe COVID-19 illness are moderate to severe immunocompromise, and unvaccinated status + obesity, medically complex disease with dependence on respiratory technology, severe neurologic or other disability resulting in impaired airway clearance, severe asthma or chronic lung disease, severe cardiac disease, and multiple moderate to severe chronic diseases. https://www.covid19treatmentguidelines.nih.gov/tables/assessing-risk/